Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable?

Abstract

We read with great interest the case report by Shalman and colleagues who reported a21-year-old male patient with Guillain-Barré syndrome (GBS) responsive to a second course of intravenous immunoglobulin (IVIg) treatments and the responsiveness was associated with the albumin level in serum [1]. This case report is interesting, and its finding is consistent with a former clinical trial suggesting that serum albumin could be a potential biomarker to monitor the treatment responses to IVIg among patients with GBS [2].